kawasaki
diseas
kd
acut
system
vascul
occur
infant
children
approxim
afflict
children
develop
coronari
arteri
lesion
cal
despit
treatment
intraven
immunoglobulin
ivig
numer
studi
aim
earli
identif
diseas
measur
clinic
serolog
factor
patient
risk
develop
addit
follow
initi
treatment
approxim
patient
kd
show
resist
prolong
fever
lead
increas
incid
cal
patient
identif
patient
risk
develop
ivig
resist
allow
potenti
earli
therapeut
intervent
would
benefici
prognosi
patient
kd
score
system
develop
predict
ivig
resist
patient
kd
report
use
limit
owe
rel
low
acut
stage
kd
number
peripher
blood
monocyt
immunopathogenesi
kd
involv
system
inflamm
activ
monocyt
import
role
product
proinflammatori
cytokin
tumor
necrosi
factor
alpha
interleukin
respect
activ
monocyt
initi
activ
tolllik
receptor
tlr
coreceptor
express
activ
tlr
trigger
activ
nuclear
factorkappa
b
ubiquit
transcript
factor
control
product
lead
massiv
system
immun
respons
caus
high
among
tlr
role
cal
develop
kd
previous
studi
use
mous
model
coronari
use
lactobacillu
casei
cell
wall
extract
lccwe
induc
mous
model
coronari
arter
shown
via
pathway
along
myeloid
differenti
factor
macrophag
dendrit
cell
activ
result
product
inflammatori
cytokin
activ
trigger
product
antiinflammatori
well
proinflammatori
cytokin
regulatori
properti
involv
inhibit
monocyt
macrophag
howev
increas
serum
level
patient
kd
correl
cal
develop
acut
stage
diseas
also
consid
indic
ivig
date
role
kd
extens
studi
role
base
find
studi
aim
determin
clinic
use
measur
frequenc
circul
monocyt
predict
cal
develop
ivig
treatment
resist
well
compar
use
thirtyon
children
diagnos
kd
cha
univers
bundang
medic
center
novemb
novemb
enrol
studi
enrol
patient
met
follow
criteria
complet
kd
fever
least
follow
clinic
conjunctiv
inject
cervic
lymphadenopathi
chang
oral
mucosa
chang
extrem
fever
clinic
symptom
plu
coronari
arteri
abnorm
dilat
aneurysm
document
children
present
incomplet
kd
exclud
studi
exclud
febril
ill
resembl
kd
determin
serum
titer
antistreptolysin
antiepsteinbarr
viral
antimump
viral
antimycoplasma
antibodi
sampl
patient
kd
furthermor
perform
multiplex
polymeras
chain
reaction
nasopharyng
aspir
taken
patient
kd
common
respiratori
virus
adenoviru
respiratori
syncyti
viru
parainfluenza
viru
influenza
viru
metapneumoviru
coronaviru
rhinoviru
also
perform
neck
ultrasonographi
patient
rule
suppur
lymphaden
patient
receiv
gkg
ivig
singl
dose
time
diagnosi
treat
high
dose
oral
aspirin
mgkgday
becam
afebril
day
specifi
american
heart
associ
afterward
given
low
dose
aspirin
mgkgday
serial
echocardiographi
perform
patient
kd
time
diagnosi
month
later
studi
cal
develop
acut
stage
kd
echocardiographi
conduct
patient
singl
cardiologist
evalu
presenc
structur
heart
diseas
well
obtain
mmode
echocardiograph
paramet
includ
left
ventricular
enddiastol
dimens
lvedd
left
ventricular
endsystol
dimens
lvesd
fraction
shorten
fs
measur
intern
diamet
proxim
right
coronari
arteri
rca
proxim
left
anterior
descend
coronari
arteri
lad
classifi
patient
cal
develop
cal
without
cal
develop
cal
includ
measur
left
main
coronari
arteri
lmca
normal
anatom
variat
lmca
report
frequent
probabl
isol
dilat
lmca
without
accompani
dilat
lad
report
z
score
coronari
arteri
obtain
use
rca
lad
measur
well
nonlinear
regress
equat
base
bodi
surfac
area
bsa
calcul
z
score
rca
lad
measur
deriv
predict
valu
rca
lad
measur
patient
given
bsa
use
follow
regress
equat
report
mccrindl
et
predict
valu
lad
standard
deviat
lad
bsa
predict
valu
rca
standard
deviat
rca
bsa
z
score
calcul
divid
differ
actual
measur
rca
lad
correspond
predict
valu
correspond
standard
deviat
describ
mccrindl
et
cal
patient
dilat
score
aneurysm
focal
diffus
dilat
coronari
arteri
segment
z
score
coronari
arteri
base
maxim
intern
diamet
rca
lad
one
month
initi
diagnosi
cal
patient
normal
z
score
coronari
arteri
one
month
initi
patient
defin
ivig
nonrespond
persist
recrudesc
fever
hour
complet
initi
ivig
twentyon
children
histori
kd
autoimmun
allerg
diseas
admit
treatment
common
febril
ill
pneumonia
gastroenter
urinari
tract
infect
includ
febril
control
fc
demograph
variabl
follow
age
sex
durat
fever
initi
treatment
preval
cal
resist
ivig
venou
blood
sampl
taken
fc
admiss
patient
kd
initi
ivig
treatment
ie
day
ill
day
ivig
treatment
day
onset
fever
determin
day
one
ill
white
blood
cell
count
serum
level
hemoglobin
albumin
aspart
aminotransferas
alanin
aminotransferas
creactiv
protein
determin
ivig
treatment
patient
kd
fc
serum
sampl
store
analys
whole
blood
sampl
taken
fc
admiss
patient
kd
initi
ivig
treatment
ie
day
ill
day
ivig
treatment
fresh
aliquot
whole
blood
sampl
falcon
polystyren
tube
becton
dickinson
lincoln
park
nj
usa
incub
apcconjug
antihuman
fitcconjug
antihuman
monoclon
antibodi
ebiosci
san
diego
ca
usa
isotyp
match
monoclon
antibodi
ebiosci
use
control
incub
red
blood
cell
lyse
wash
cold
phosphatebuff
salin
fix
paraformaldehyd
total
cell
count
sampl
appropri
gate
monocyt
popul
identifi
cell
scatter
diagram
analyz
bd
facscan
immunocytometri
system
san
jose
ca
usa
use
cellquest
softwar
serum
concentr
determin
use
enzymelink
immunosorb
assay
kit
r
system
co
minneapoli
mn
usa
briefli
use
quantit
sandwich
enzym
immunoassay
techniqu
micropl
precoat
human
monoclon
antibodi
buffer
protein
base
standard
control
sampl
ad
per
well
incub
wash
wash
buffer
human
conjug
ad
incub
anoth
wash
substrat
solut
ad
color
well
turn
blue
yellow
optic
densiti
well
determin
use
micropl
reader
r
system
co
accord
manufactur
instruct
procedur
involv
human
particip
perform
studi
accord
ethic
standard
institut
review
board
cha
univers
bundang
medic
center
well
helsinki
declar
later
amend
compar
ethic
standard
parent
guardian
children
particip
studi
provid
written
inform
consent
approv
ethic
committe
cha
univers
bundang
medic
center
valu
express
deviat
appropri
percentag
comparison
variabl
made
use
mannwhitney
u
test
continu
variabl
chisquar
test
categor
variabl
correl
analysi
perform
use
spearman
coeffici
determin
cutoff
valu
predict
cal
develop
ivig
resist
receiv
oper
characterist
roc
curv
analysi
perform
statist
analys
done
use
ibm
spss
statist
ver
ibm
co
armonk
ny
usa
p
valu
consid
statist
signific
studi
clinic
characterist
patient
kd
agematch
fc
tabl
patient
kd
day
onset
fever
design
day
one
ill
eleven
patient
kd
develop
cal
month
initi
diagnosi
patient
ivig
nonrespond
patient
cal
time
initi
diagnosi
whose
coronari
z
score
normal
month
consid
transient
lesion
categor
cal
group
accord
method
previous
propos
yoshimura
et
studi
correl
ntermin
probrain
natriuret
peptid
cal
ivig
resist
acut
stage
kd
percentag
ivig
nonrespond
significantli
differ
cal
cal
group
patient
versu
patient
respect
percentag
cal
patient
significantli
differ
ivig
nonrespond
ivig
respond
versu
respect
echocardiographi
patient
kd
reveal
signific
structur
heart
defect
except
small
hemodynam
insignific
patent
foramen
oval
one
patient
small
amount
mitral
regurgit
notic
four
patient
kd
cal
group
cal
group
consid
hemodynam
insignific
signific
differ
lvedd
lvesd
fs
found
cal
cal
group
ivig
nonrespond
ivig
respond
tabl
paramet
previous
determin
correl
increas
risk
develop
cal
ie
age
durat
fever
white
blood
cell
count
serum
albumin
creactiv
protein
none
statist
differ
cal
cal
group
predict
durat
fever
ivig
treatment
significantli
longer
ivig
nonrespond
compar
ivig
respond
among
paramet
previous
found
correl
risk
ivig
level
serum
hemoglobin
alanin
aminotransferas
significantli
higher
ivig
nonrespond
compar
ivig
respond
express
repres
case
cal
cal
fc
group
shown
fig
prior
initi
treatment
significantli
increas
cal
group
compar
cal
group
vs
respect
p
tabl
initi
treatment
usual
increas
ivig
nonrespond
compar
ivig
respond
statist
signific
differ
two
group
vs
respect
p
tabl
shown
tabl
signific
differ
initi
treatment
patient
kd
fc
group
cal
cal
group
patient
kd
initi
treatment
usual
higher
ivig
nonrespond
compar
ivig
respond
result
statist
signific
addit
patient
kd
correl
significantli
patient
kd
correl
significantli
previous
determin
risk
factor
cal
known
predictor
ivig
addit
patient
correl
significantli
echocardiograph
variabl
lvedd
lvesd
fs
cutoff
valu
predict
cal
obtain
roc
curv
area
curv
respect
cutoff
valu
predict
cal
sensit
specif
wherea
cutoff
valu
pgml
predict
cal
sensit
specif
area
roc
curv
identifi
ivig
nonrespond
use
respect
cutoff
valu
predict
ivig
resist
sensit
specif
wherea
cutoff
valu
pgml
predict
ivig
resist
sensit
specif
studi
show
initi
treatment
patient
kd
significantli
high
cal
group
cal
group
sensit
predict
paramet
cal
furthermor
tend
higher
ivig
nonrespond
compar
ivig
respond
frequenc
could
predict
ivig
resist
sensit
compar
best
knowledg
studi
first
clinic
studi
util
predict
cal
develop
ivig
resist
patient
kd
compar
feasibl
previou
studi
tlr
kd
focus
feasibl
coronari
arter
anim
model
elucid
pathophysiolog
mechan
involv
cal
develop
kd
elev
level
tlr
kd
regardless
cal
role
express
cal
develop
kd
studi
use
coronari
arter
mous
model
induc
lccwe
shown
involv
induc
focal
coronari
feasibl
lccwe
mous
model
repres
mechan
tlr
activ
patient
kd
investig
lin
et
report
patient
kd
lccwe
mous
model
develop
similar
cardiac
lesion
well
coronari
arter
similar
pattern
cytokin
increas
note
elev
acut
phase
kd
patient
kd
lccwe
mous
model
report
also
show
patient
kd
ivig
treatment
lccwe
mous
model
surfac
express
circul
monocyt
increas
agre
result
show
increas
cal
group
compar
cal
group
howev
studi
lin
et
investig
correl
tlr
express
level
cal
develop
ivig
resist
moreov
activ
may
earli
upstream
respons
preced
product
proinflammatori
cytokin
eg
shown
import
cal
may
time
lag
activ
subsequ
product
proinflammatori
cytokin
monitor
could
potenti
use
rel
earli
predictor
cal
develop
elev
serum
cytokin
level
becom
clinic
appar
evid
use
tlr
express
monitor
cardiovascular
diseas
burden
sever
found
studi
meth
et
show
increas
tlr
express
level
involv
progress
atherosclerot
lesion
demonstr
expans
circul
monocyt
patient
acut
coronari
suggest
base
result
result
meth
et
tlr
express
level
could
use
monitor
cardiovascular
diseas
burden
sever
kd
addit
use
whole
blood
measur
tlr
express
requir
rel
step
suggest
tlr
potenti
easytous
biomark
result
show
initi
treatment
sensit
predictor
cal
develop
patient
kd
treatment
shown
elev
patient
acutestag
kd
cutoff
valu
predict
cal
develop
ivig
resist
previous
found
treatment
cal
group
significantli
higher
cal
group
reason
find
might
studi
patient
belong
cal
group
develop
cal
one
month
diagnosi
high
acut
stage
kd
might
cumul
benefici
effect
inflamm
coronari
past
acut
stage
kd
known
antiinflammatori
proinflammatori
studi
initi
treatment
ivig
nonrespond
tend
higher
ivig
respond
addit
result
show
sensit
predict
ivig
resist
patient
kd
compar
initi
treatment
one
numer
mechan
action
ivig
kd
inhibit
activ
macrophag
monocyt
ivig
involv
downstream
tlr
signal
pathway
may
indic
ivig
nonrespond
increas
initi
treatment
would
lead
increas
activ
thu
requir
addit
treatment
ivig
studi
need
confirm
addit
known
predict
marker
ivig
monitor
could
use
predict
ivig
resist
patient
kd
earli
identif
patient
risk
cal
develop
ivig
resist
monitor
could
supplement
exist
guidelin
addit
intens
treatment
strategi
earli
combin
corticosteroid
therapi
addit
initi
ivig
treatment
propos
kobayashi
et
earli
cours
kd
initi
treatment
correl
significantli
lvedd
lvesd
fs
find
line
previous
report
result
show
consist
associ
left
ventricular
lv
function
patient
kd
laboratori
indic
system
possibl
sensit
method
assess
lv
function
lv
longitudin
strain
known
correl
serum
albumin
level
patient
could
also
potenti
correl
inclus
rel
small
number
patient
investig
present
limit
studi
might
affect
result
statist
analys
lead
difficulti
show
correl
previous
determin
risk
factor
cal
develop
ivig
resist
anoth
limit
might
rel
shortterm
followup
patient
cal
form
month
onset
diseas
addit
prospect
studi
initi
treatment
could
affect
subsequ
result
echocardiogram
taken
month
later
moreov
regul
interact
tlr
inflammatori
cytokin
occur
complex
therefor
studi
need
elucid
correl
separ
monocyt
whole
blood
studi
therefor
small
number
cell
monocyt
may
analyz
howev
accord
aim
studi
establish
potenti
marker
kd
sever
prognosi
thought
use
whole
blood
sampl
serv
easier
appropri
approach
furthermor
cal
group
show
increas
initi
treatment
compar
cal
group
propos
time
endogen
ligand
might
respons
delay
stimul
addit
initi
stimulu
respons
earli
find
may
limit
use
prognost
paramet
initi
treatment
studi
focus
acut
chang
cal
kd
diseas
onset
longterm
followup
studi
need
elucid
longterm
effect
coronari
arteri
kd
addit
investig
ligand
capabl
activ
kd
would
help
conclus
show
measur
initi
treatment
could
use
predict
marker
cal
patient
kd
better
sensit
result
demonstr
initi
treatment
could
also
predict
ivig
resist
sensit
compar
studi
involv
larger
number
patient
kd
need
valid
marker
prognosi
sever
kd
